Business Context and Reporting Period
This Form 8-K filing by iBio, Inc. (Delaware) covers the reporting period ending May 31, 2013, with the report signed on June 5, 2013. The filing addresses the company's status regarding its listing on the NYSE MKT.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. However, it references a prior notice from the Exchange indicating that the company has sustained substantial losses relative to its operations and financial resources, raising questions about its ability to continue operations or meet obligations.
Material Changes
The primary material event is the resolution of a delisting notice. On April 22, 2013, iBio received notice of non-compliance with NYSE MKT Section 1003(a)(iv) due to financial impairment. On May 31, 2013, the Exchange accepted iBio's plan of compliance and granted an extension until October 14, 2013, to regain compliance.
Outlook, Risks, and Contingencies
- Compliance Extension: iBio has until October 14, 2013, to meet continued listing standards.
- Delisting Risk: Failure to make progress consistent with the accepted plan or to regain compliance by the extension deadline could result in delisting from the NYSE MKT.
- Monitoring: The company will be subject to periodic review by the Exchange staff during the extension period.
Investor Verification Checklist
- Verify the specific details of the compliance plan submitted to the NYSE MKT.
- Monitor periodic progress reports required by the Exchange during the extension period.
- Review the attached press release (Exhibit 99.1) for additional management commentary on the financial condition.
- Assess the company's ability to meet the October 14, 2013, deadline to avoid delisting.